NCT01591200View on ClinicalTrials.gov

Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Alcoholic Liver Cirrhosis
Interventions
BIOLOGICAL

Allogeneic Mesenchymal Stem Cells

High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery

BIOLOGICAL

Allogeneic Mesenchymal Stem Cells

Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery

BIOLOGICAL

Allogeneic Mesenchymal Stem Cells

Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery

Trial Locations (10)

226014

SGPGI Lucknow, Lucknow

302004

SMS Medical college and Hospital, Jaipur

400012

Institute of liver disease, HPB surgery and transplant Global Hospitals, Mumbai

400020

Bombay Hospital & Medical Research Center, Mumbai

411001

Ruby Hall clinic, Pune

411004

Sahyadri Speciality Hospital, Pune

500058

Centre for Liver Research & Diagnostics, Hyderabad

500063

Mediciti Hospital, Hyderabad

560017

Manipal Hospital, Bangalore

575001

KMC Hospital, Mangalore

All Listed Sponsors
lead

Stempeutics Research Pvt Ltd

INDUSTRY

NCT01591200 - Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis | Biotech Hunter | Biotech Hunter